All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
During the 2022 ASCO Annual Meeting, the AML Hub spoke with Curtis Lachowiez, MD Anderson Cancer Center, Houston, US. We asked for an update on triplet therapy with ivosidenib, venetoclax, and azacitidine.
Update on triplet therapy with ivosidenib, venetoclax, and azacitidine.
In this video, Lachowiez discusses an updated analysis of the completed phase Ib portion of the study of ivosidenib combined with venetoclax, either with/without azacitidine, presented at ASCO 2022. Lachowiez outlines the study design and enrollment criteria, then goes on to discuss adverse effects and response rates for the different patient groups. Finally, Lachowiez describes findings on IDH-1 clearance rates, overall survival, MRD, and the upcoming phase II expansion cohorts.
The history and evolution of the role of venetoclax in the treatment of AML
Despite only being approved in the last few years, venetoclax has already become a standard of care for treating patients with acute myeloid leukemia (AML). In a talk during...
"How I treat": case studies to address new challenges encountered in the treatment of AML
The “How I Treat” series in Blood aims to offer diagnostic or therapeutic advice for a disease or several distinct aspects of a single disorder. There have been...
Subscribe to get the best content related to AML delivered to your inbox